FindTrial
Sign In

EMB-01

DRUG5 trials

Sponsors

Shanghai EpimAb Biotherapeutics Co., Ltd., Rose Research Center, LLC

Conditions

Advanced Lung Non-Small Cell CarcinomaEGFR Mutation-Related TumorsMetastatic Gastrointestinal Carcinoid TumorMetastatic Lung Non-Small Cell CarcinomaNeoplasm MetastasisNeoplasmsNon-Small-Cell Lung CancerSmoking Cessation

Phase 1

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
NCT03797391
Shanghai EpimAb Biotherapeutics Co., Ltd.Neoplasm Metastasis, Neoplasms, Non-Small-Cell Lung Cancer
Start: 2018-12-13End: 2026-01-15Target: 186Updated: 2023-05-31
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RecruitingNCT05176665
Shanghai EpimAb Biotherapeutics Co., Ltd.Metastatic Gastrointestinal Carcinoid Tumor, Neoplasm Metastasis, Neoplasms
Start: 2021-10-21End: 2025-12-31Target: 152Updated: 2024-08-26
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
NCT05498389
Shanghai EpimAb Biotherapeutics Co., Ltd.Advanced Lung Non-Small Cell Carcinoma, EGFR Mutation-Related Tumors, Metastatic Lung Non-Small Cell Carcinoma +6
Start: 2023-06-30End: 2024-12-31Target: 115Updated: 2023-06-01
EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer
Not yet recruitingNCT07649655
Shanghai EpimAb Biotherapeutics Co., Ltd.Unresectable/Metastatic Colorectal Cancer
Start: 2026-07-01End: 2028-12-31Target: 120Updated: 2026-06-16

Phase 2

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
NCT04868253
Rose Research Center, LLCSmoking Cessation, Tobacco Use Disorder
Start: 2021-05-19End: 2021-12-31Target: 25Updated: 2021-05-28

Related Papers

EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer From a Phase Ib/II, Open-Label, Multicenter Study.
2026-08-24
EMB-01, a tetravalent anti-EGFR/cMET bispecific antibody, in the left-sided, RAS/BRAF wild-type, late-line metastatic colorectal cancer: Subgroup analysis of baseline characteristics and response from a phase 1/2 study.
Journal of Clinical Oncology2026-01-10
Abstract CT168: EMB-01, an EGFR/cMET bispecific antibody, in metastatic colorectal cancer: Results from an international phase Ib/II study
Cancer Research2025-04-251 citations